Rescue therapy with polymyxin B hemoperfusion in high-dose vasopressor therapy refractory septic shock.

Abstract

This is the first study describing the use of PMX-HP as a rescue therapy in RSS patients with HDVT and MOF. Our results suggest a possible role for PMX-HP in improving hemodynamics, organ function, and mortality in RSS, with a 30-day survival of up to 70%.